Microbiology Diagnostic Devices and Equipment Global Market Report 2024

The microbiology diagnostic devices and equipment market size has grown rapidly in recent years. It will grow from $4.49 billion in 2023 to $5.02 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth observed in the historical period can be attributed to increased healthcare expenditure, the growth of emerging markets, rapid technological advances, the swift expansion of the aging population, and the emergence of novel pathogenic infestations.

The microbiology diagnostic devices and equipment market size is expected to see rapid growth in the next few years. It will grow to $7.74 billion in 2028 at a compound annual growth rate (CAGR) of 11.4%. The anticipated growth in the forecast period can be attributed to a rise in funding, the aging population, an increase in healthcare access, and a rapid increase in various bacterial and viral epidemics. Key trends in the forecast period include the growing adoption of predictive diagnostics, automation in the field of microbiology diagnostics, next-generation microbial testing, and an increasing number of mergers and acquisitions.

The growth of the microbiology diagnostic devices market is being propelled by increased funding from both public and private investments in medical devices. The surge in investments reflects the growing confidence of various private and public stakeholders in microbiology diagnostic devices, signaling a positive trend and fostering market growth. For instance, MedTech news reported that the private equity industry invested $111.8 billion (approximately $151 billion) in the healthTech industry. Globally, 96 deals valued at $40.8 billion were completed in the medTech vertical. This heightened investment focus on digital health technologies, artificial intelligence, non-invasive monitoring capabilities, gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices is anticipated to drive the microbiology diagnostic devices market.

The increasing prevalence of chronic diseases is expected to contribute significantly to the growth of the microbiology diagnostic devices and equipment market in the foreseeable future. Chronic diseases, characterized by long-lasting or persistent medical conditions, are on the rise and necessitate effective management through the detection, treatment, and prevention of microbial infections and associated complications. According to the World Health Organization (WHO), chronic diseases account for 74% of global deaths, with conditions such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contributing to the majority of fatalities. This growing prevalence of chronic diseases is a key driver for the microbiology diagnostic devices and equipment market.

Next-Generation Sequencing (NGS) technologies are gaining prominence in the microbiology diagnostic devices market due to their cost-effectiveness, sensitivity in detecting low-frequency variants, and comprehensive genomic coverage. NGS, also known as high throughput sequencing or Massively Parallel Sequencing (MPS), offers the ability to sequence hundreds to thousands of genes or gene regions and detect novel resistance genes (ARG) in bacteria. BioMérieux's collaboration with Illumina resulted in the development of bioMérieux EpiSeq, an NGS service facilitating epidemiological monitoring of bacterial infections and outbreak monitoring in hospitals. Notable NGS technologies include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing.

Major companies in the microbiology diagnostic devices and equipment market are introducing innovative systems, such as third-generation total lab automation (TLA) systems, to enhance laboratory testing efficiency, accuracy, and cost-effectiveness. These advanced TLA systems automate various laboratory tasks, from specimen processing and plating to incubation, imaging, and culture reading. Becton, Dickinson, and Company (BD) launched third-generation TLA systems in January 2023, featuring a modular design, a robotic track system, advanced informatics solutions, and integration of artificial intelligence (AI). This system is customizable for a variety of tasks in a microbiology laboratory, making it a valuable tool for laboratories seeking improved efficiency, cost reduction, and enhanced patient care.

In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics to strengthen its position in the point-of-use testing and sampling markets for both humans and animals. Biomed Diagnostics is a US-based microbiological testing company.

Major companies operating in the microbiology diagnostic devices and equipment market report are Danaher, Abbott Laboratories, Thermo Fisher Scientific, Becton Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc., Roche, Bruker Corporation, Charles River Laboratories International Inc., Merck KGaA, Johnson & Johnson, Simens Healthcare, Beckman Coulter Inc., Ortho Clinical Diagnostics, Sysmex Corporation, Siemens Healthineers, TestLine Clinical Diagnostics s.r.o., Cepheid, Hologic, Bayer AG, Cantel Medical Corporation, Meridian Bioscience, Qiagen N.V., Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc., PerkinElmer, Inc., Adavium Medical, DK Diagnostics, Crosmed, Ortopedia Alemana, Simed, Shalina Healthcare, Elixir Medical Equipment LLC (EME), Matrix Medical, Gulf Medical Co, Almarfa Medical, Lithotech Medical, Neogen Corporation.

North America was the largest region in the microbiology diagnostics devices and equipment market in 2023. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market. The regions covered in the microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the microbiology diagnostic devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The primary types of microbiology diagnostic devices and equipment comprise laboratory instruments, microbiology analyzers, and reagents and consumables. Laboratory instruments encompass items such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems, which are essential for laboratory operations. Reagents include pathogen-specific kits and general reagents used across various end-users, including diagnostic laboratories, hospitals, and others.

The microbiology diagnostics devices and equipment market research report is one of a series of new reports that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.